E-ISSN 2602-3164
EJMI. 2024; 8(3): 173-183 | DOI: 10.14744/ejmi.2024.69932

Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Clinical, Pathological and Survival Characteristics and Factors Predicting Complete Response

Mukaddes Yılmaz1, Eda Erdis2, Mahmut Ucar1, Birsen Yücel2
1Department of Medical Oncology, Cumhuriyet University Faculty of Medicine, Sivas, Türkiye, 2Department of Radiation Oncology, Cumhuriyet University Faculty of Medicine, Sivas, Türkiye

Objectives: To investigate the clinical, pathological, and survival characteristics of locoregional breast cancer patients receiving neoadjuvant chemotherapy (NACT). Methods: Breast cancer patients at Cumhuriyet University Oncology Center between January 2010 and December 2022 were evaluated retrospectively. Results: The study included 177 patients. After NACT, 43 (24%) of the patients achieved pCR. Pre-NACT clinicopatholog ical data, including age (p=0.045), cN stage (p=0.038), ER status (p=0.004), PR status (p=0.019), HER2 status (p<0.001), Ki-67 percentage (p=0.001), molecular subtyping (p<0.001), axillary intervention (p<0.001), use of adjuvant hormone therapy (p=0.002), grade (p=0.044), distant metastasis (p<0.001), overall survival (OS, p=0.005), and disease-free surviv al (DFS, p=0.003), were significantly different between patients who achieved pCR and nonpCR patients. Menopausal status (p=0.044), HER2 status (p<0.001), Ki-67 status (p=0.001), molecular subtyping (p=0.031), and pertuzumab use (p=0.044) were identified as predictive factors for pCR. Conclusion: Patients who achieved pCR were younger; had higher Ki-67 percentage; had lower ER and PR positivity; had higher HER2 positivity; had grade 3 disease; and had better OS and DFS. Being premenopausal, having HER2 posi tivity, having a Ki-67 percentage greater than 25, being in the HER2-positive molecular subtype, and receiving pertu zumab were favorable predictive factors for pCR. Keywords: Breast cancer, clinical features, d


Cite This Article

Yılmaz M, Erdis E, Ucar M, Yücel B. Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Clinical, Pathological and Survival Characteristics and Factors Predicting Complete Response. EJMI. 2024; 8(3): 173-183

Corresponding Author: Mukaddes Yılmaz

Full Text PDF PDF Download
EJMI & EJMI